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Abstract
Background: Discomfort characterized by pain and warmth are common adverse effects associated with the use of
intra-arterial iodinated contrast media (CM). The objective of this review was to pool patient-reported outcomes
available from head-to-head randomized controlled trials (RCTs) and to compare the discomfort rates associated with
iso-osmolar contrast media (IOCM; i.e., iodixanol) to those reported with various low-osmolar contrast media (LOCM).
Methods: A review of the literature published between 1990 and 2009 available through Medline, Medline
Preprints, Embase, Biological Abstracts, BioBase, Cab Abstracts, International Pharmaceutical Abstracts, Life Sciences
Collection, Inside Conferences, Energy Database, Engineering Index and Technology Collection was performed
to compare rates of discomfort associated with the use of the IOCM (iodixanol) vs. various LOCM agents in
head-to-head RCTs. All trials with a Jadad score ≥2 that reported patient discomfort data following intra-arterial
administration of CM were reviewed, coded, and extracted.
Results: A total of 22 RCTs (n = 8087) were included. Overall discomfort (regardless of severity) was significantly
different between patients receiving IOCM and various LOCMs (risk difference [RD] -0.049; 95% confidence interval [CI]:
-0.076, -0.021; p = 0.001). IOCM was favored over all LOCMs combined with a summary RD value of -0.188 (95% CI:
-0.265, -0.112; p < 0.001) for incidence of pain, regardless of severity. A greater reduction in the magnitude of pain was
observed with IOCM (iodixanol), particularly with selective limb and carotid/intracerebral procedures. Similarly, the
meta-analysis of warmth sensation, regardless of severity, favored IOCM over LOCMs with an RD of -0.043 (95% CI:
-0.074, -0.011; p = 0.008). A positive linear relationship was observed between the discomfort effect size and age and a
negative relationship with increasing proportion of women. The opposite trends were observed with warmth sensation.
Conclusions: IOCM was associated with less frequent and severe patient discomfort during intra-arterial
administration. These data support differences in osmolality as a possible determinant of CM discomfort.
Keywords: contrast, discomfort, pain, intravascular, meta-analysis
Background
Iodinated contrast media (CM) are essential to intravascu-
lar imaging procedures utilizing ionizing radiation. The
development of CM has progressed from high-osmolar
contrast media (HOCM) with osmolality (particle concen-
tration in milliosmoles per kilogram of water) of ~2000
mOsm/kg, to low-osmolar contrast media (LOCM) with a
range of ~600-800 mOsm/kg, to iso-osmolal contrast
media (IOCM) at 290 mOsm/kg that is isotonic to blood
[1]. The intensity and frequency of adverse-effects asso-
ciated with intravascular CM injections were reduced con-
siderably with changes in usage from HOCM to LOCM.
Nevertheless, patient discomfort during the intravascular
administration remains a clinical challenge [2].
More than a third of patients in controlled clinical
trials have been known to report CM-injection-related
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unpleasant sensation of warmth [3]. The degree of dis-
comfort and tolerability, generally considered to be
directly proportional to the osmolality of CM, can influ-
ence the quality of the examination. Pain and discomfort
may cause patients to move, thus resulting in motion
artifacts and suboptimal images. Thus, it is of clinical
value to further improve patient comfort and the diag-
nostic quality of radiological images [4].
Practice recommendations and guidelines issued by
national societies have focussed on the risk of renal and
cardiac complications after contrast and have not con-
sidered potential differences in pain and discomfort [5].
Likewise, most reviews and meta-analyses available in
the literature have reported on contrast-induced acute
kidney injury as the outcome of interest [1,6-9]. Patient-
reported subjective outcomes are infrequently reported
in the radiology literature [10]. It is widely believed by
radiologists that iso-osmolal contrast causes less discom-
fort that higher osmolar contrast media; there has not
been definitive evidence to support this notion. There-
fore, the goals of the current study were to pool data
available from head-to-head randomized controlled trials
(RCTs) and compare the frequency and severity of dis-
comfort associated with IOCM (iodixanol) to those
reported with various LOCM agents.
Methods
Search Strategy
A comprehensive search of the literature published from
1990 to Aug 2009 was performed by Nerac Inc. (Tol-
land, CT) using the following search string: (Visipaque*;
iodixanol; 92339-11-2\RN\AL\SU\TM) and (tolerab*;
tolerat*; *comfort; warmth; pain*; heat; warm\AL) and
(double blind*; double-blind*;p r o s p e c t i v e ;r a n d o m i z e d ;
randomized; head <2> head; parallel\AL) on August 27,
2009. The search was not limited to English language.
Study Selection and Data Extraction
The resources utilized along with total number of refer-
ences located from each resource were: Medline (51);
Medline Preprints (4); Embase (56); Biological Abstracts
(8); BioBase (2); Cab Abstracts (1); International Phar-
maceutical Abstracts (0); Life Sciences Collection (4);
Inside Conferences (0); Energy Database (5); Engineering
Index (1); and Technology Collection (0). Duplicate cita-
tions (57) were removed from the search results, and the
remaining 75 abstracts were further reviewed for
relevance.
A flow diagram illustrating the process of elimination
used to select set of studies that met the inclusion/
exclusion criteria for the meta-analysis is presented in
Figure 1. Studies that were not relevant to the topic of
research, did not meet all the inclusion criteria, or were
either review articles or meta-analyses were excluded.
Additionally, studies using intravenous (IV) administra-
tion of CM were eliminated since the focus of the
current study was limited to studies with intra-arterial
(IA) administration of CM.
Data relating to more than 25 parameters were
extracted from the RCTs, when available, into a standar-
dized Microsoft
® Excel (Redmond, WA) template and
were assessed for quality and consistency by indepen-
dent parties. The validated 5-point Jadad scale was used
as an instrument for measuring the quality of each RCT
with a score of 5 being indicative of excellent quality on
a scale of 0 to 5 [11]. Only studies with a Jadad score of
≥ 2 were included in the meta-analysis.
Statistical Analyses
Descriptive statistics were reported as means ± standard
deviations and counts with proportions as appropriate.
Demographic summaries included gender, race, age, and
weight for each study population, when available. Base-
line characteristics were compared using the Student’st -
test, Chi-square, or Wilcoxon rank sum test of the
weighted averages, as appropriate.
The risk difference (RD) of pain, discomfort, warmth,
and cold between IOCM (iodixanol) and the combined
LOCM agents was determined. The first RD analysis
was based on the incidence of an event, regardless of
severity, while the second RD analysis evaluating severity
was performed by grouping no events and mild events
together and comparing this group to those with moder-
ate and severe events. A subset analysis was performed
between IOCM (iodixanol) and each LOCM agent. A
meta-analysis was carried out by using the random-
effects model of DerSimonian and Laird to calculate
pooled RDs and associated 95% confidence intervals
(CIs) for outcomes [12]. This method was chosen
because it works independently of heterogeneity and
coincides with the inverse variance fixed-effects model if
there is no heterogeneity [12].
Statistical heterogeneity of trial results was tested
using the Cochran Q statistic and I
2, which indicate the
percentage of the variability in effect estimates because
of heterogeneity rather than chance. For the Q statistic,
p<0 . 1 0w a sc o n s i d e r e ds i g n i f i c a n t .S u b g r o u pa n a l y s e s
to assess the effect of increasing age and percentage of
female patients were performed using meta-regression
analysis. Data were also examined for potential publica-
tion bias using the Egger and Begg tests as well as fun-
nel plots where RDs were plotted against their
corresponding standard errors [13,14]. All statistical
tests were 2-sided tests with p < 0.05 regarded as statis-
tically significant. Analyses were done using SAS
® (Cary,
NC) Version 9.1 and Comprehensive Meta-Analysis
Version 2.
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Following the elimination of duplicates from the search
results, a total of 75 abstracts were reviewed with 21
articles meeting the predetermined inclusion criteria
and one study being added from prior knowledge of the
literature as shown in Figure 1. Fifty-one abstracts
excluded for the following reasons: 17 studies were pre-
clinical, involved skin testing, hemodynamic assessment,
oral hydration, comparative technologies, or had no
patient reported outcomes; 13 studies did not use
IOCM (iodixanol), were not head-to-head IOCM (iodix-
anol) versus LOCM, or were not blinded; 11 studies
used IV administration; and 10 were meta-analysis and
review articles. No attempts were made to contact study
authors to either confirm the published trial results or
include any unpublished trial results.
The study quality was generally excellent for the RCTs
included, with a Jadad score ≥ 2. Most of the articles
included a discussion of pain, discomfort or warmth.
Some studies were included more than once in the
meta-analysis according to the parameter reported, thus
the numbers of articles discussed when totaled summed
to more than 22 in some instances.
Characteristics of Reviewed Studies
Table 1 shows an overview of the studies included [15-36].
The patient population sizes for all the reviewed trials,
with the exception of three large studies, ranged from 19
to 165 per treatment group; the number enrolled in each
of the large studies was greater than 1000 [15-17]. The
average age among the 22 trials (n = 8087) was similar
between the two groups, 62.5 years for IOCM (iodixanol)
and 61.7 years for all LOCMs combined. The proportions
of female patients in the IOCM (iodixanol) and LOCM
groups were similar (29% and 30.5%, respectively).
Although the average body weight, when compared for
the individual IOCM (iodixanol) versus LOCM trials
appeared to be similar, patients in the pooled IOCM
(iodixanol) arms had significantly lower body weight than
those in all LOCM groups combined (74.5 kg vs. 80.2 kg,
respectively). The individual LOCMs compared in the
trials included iohexol, ioxaglate, iopamidol, and iomeprol.
Figure 1 Flow chart outlining literature search and study selection strategy.
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Study Injection Site and/or Procedure Treatment
group
Number of patients
in comfort analysis
Number (%)
of Females
Age
(Mean
[SD])
Weight
(Mean
[SD])
Andersen et al[28] Left ventricle & selective coronary artery
injections (left and right)
Iodixanol 36 9 (25.0) 54 81
Ioxaglate 38 13 (34.2) 56 77
Fischbach et al[29] Celiac trunk/spiral CT angiography
of abdominal aorta
Iodixanol 40 10 (25.0) 65.7 ± 11.4 77.1 ± 14.7
Ioversol 38 6 (15.8) 61 ± 11.1 78 ± 11.5
Flinck et al[30] Cardioangiography Iodixanol 44 8 (18.2) 62.5 80
Ioxaglate 44 8 (18.2) 62.5 80
Hekster et al[31] Multiple carotid and vertebral
arteries/IA cerebral DSA
Iodixanol 40 16 (40.0) 61 74
Iohexol 39 14 (35.9) 57 71
Hill et al[32] Coronary and left ventricular angiography Iodixanol 101 20 (19.8) 61 ± 10.0 unknown
Iohexol 99 12 (12.1) 59 ± 11.0 unknown
Justesen et al[15] Femoral arteriography Iodixanol 1225 343 (28.0) 65.6 ± 11.5 71.8 ± 12.5
Iopromide 1227 339 (27.6) 65 ± 11.3 71.7 ± 12.9
Kendall et al[24] IA cerebral digital subtraction angiography Iodixanol 44 22 (50.0) 49.7 ± 11.0 70.2 ± 13.5
Iohexol 42 24 (57.1) 45.7 ± 13.3 70.9 ± 13.4
Klow et al[33] Left ventriculography, selective coronary
arteriography, and thoracic aortography
Iodixanol 35 unknown 54 ± 9.0 80 ± 10.0
Iohexol 37 unknown 55 ± 9.0 81 ± 13.0
Manke et al[22] Femoral arteriography Iodixanol 163 22 (13.5) 63.6 ± 11.2 74.4 ± 12.9
Iomeprol 165 36 (21.8) 65.2 ± 11.6 74.8 ± 12.6
Manninen et al[34] IA Iodixanol 50 24 (48.0) 69 unknown
Iohexol 50 24 (48.0) 69 unknown
Palmers et al[25] Cerebral arteriography Iodixanol 40 14 (35.0) 54.9 69.7
Ioxaglate 40 18 (45.0) 48.9 73.9
Poirier et al [18] Cerebral angiography Iodixanol 51 unknown unknown unknown
Iohexol 48 unknown unknown unknown
Pugh et al [19] Femoral arteriography Iodixanol 48 12 (25.0) 65 ± 8.9 74.3 ± 14.7
Iopromide 47 13 (27.7) 68 ± 10.4 73.9 ± 12.1
Roriz et al [26] Left ventricular cardioangiography Iodixanol 54 13 (24.1) 58 ± 11.0 75 ± 9.0
Ioxaglate 53 13 (24.5) 57 ± 10.0 75 ± 12.0
Rosenblum et al [27] Peripheral and aortic angiography Iodixanol 19 13 (68.4) 64 ± 11.0 76 ± 18.0
Ioxaglate 25 9 (36.0) 68 ± 9.0 76 ± 16.0
Siegel et al [21] Aortography, renal/visceral angiography Iodixanol 29 11 (37.9) 51 ± 19.0 76 ± 17.0
Ioxaglate 25 9 (36.0) 52 ± 15.0 74 ± 18.0
Singh et al [35] Abdominal aorta/Abdominal angiography Iodixanol 39 10 (25.6) 59.1 70.3
Iohexol 20 8 (40.0) 66.1 70.3
Sutton et al [16] Cardiac catheterization/femoral
arteriography
Iodixanol 468 173 (37.0) 60.2 ± 10.0 76.5 ± 14.7
Ioxaglate,
Iopamidol
1128 367 (32.5) 60.3 95.1
Sutton et al [17] Cardiac catheterization/coronary
angiography
Iodixanol 665 222 (33.4) 60.7 ± 10.2 78 ± 14.0
Iopamidol,
Iomeprol
1443 505 (35.0) 60.4 78.5
Thorstensen et al [23] Femoral arteriography Iodixanol 73 31 (42.5) 67.6 ± 12.5 68 ± 12.9
Iohexol 74 33 (44.6) 67.8 ± 11.3 70.2 ± 14.5
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Thirteen of the 22 trials included data on patient discom-
fort associated with intra-arterial injections (n = 3567)
and most of these data did not report severity of discom-
fort (Figure 2A). In the 2 studies that reported severity,
more than 50% of the patient population classified the
sensation as mild [18,19]. There was a significant, though
small, difference observed in patient discomfort regard-
less of severity between IOCM (iodixanol) and all
LOCMs (the overall RD was -0.049 (95% confidence
interval [CI]: -0.076, -0.021; p = 0.001) in favor of IOCM
(iodixanol). Heterogeneity across studies was observed
(Cochran’s Q = 21.247; p = 0.047; I
2 = 43.5) (Figure 2B).
IOCM (iodixanol) was the favored CM both when the
trial data were analyzed individually against each LOCM
(ioxaglate, iohexol, iopromide) for discomfort regardless
of severity and for all LOCMs combined as a group. The
number of studies identified for iopamidol (n = 1) and
iomeprol (n = 0) was not adequate to allow the meta-ana-
lysis for incidence of discomfort to be performed for
these LOCMs. However, the IOCM iodixanol was
favored when compared to iopamidol (p = 0.028) [20].
Table 1 Study characteristics of RCTs included in the meta-analysis (Continued)
Tveit et al [36] Left ventricular cardioangiography Iodixanol 53 9 (17.0) 58 76.9
Ioxaglate 49 12 (24.5) 58 77.9
Verow et al [20] Aorta/Femoral arteriography Iodixanol 68 unknown unknown unknown
Iopamidol 65 unknown unknown unknown
Combined papers Iodixanol 3385 982 (29) 62.5 74.5*
All LOCMs
Combined
4796 1463 (30.5) 61.7 80.2
*Indicates significant difference between groups (p < 0.05).
Figure 2 A. Incidence of any discomfort (regardless of severity) associated with CM injections organized by region. B. Meta-analysis of
incidence of CM-associated discomfort (regardless of severity) - IOCM (iodixanol) vs. LOCMs.
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Figure 3 presents the incidence of CM-associated pain
based on severity in three panels: Panel A illustrates the
incidence data on pain, based on severity, reported by a
total of 7 trials (n = 881); Panel B illustrates the assess-
ment of any pain associated with CM injections in 10
trials (n = 3482); and Panel C illustrates results from the
meta-analysis. Contrary to the observations in patient
discomfort studies discussed above, a more pronounced
difference was evident in the incidence of pain between
IOCM (iodixanol) and LOCM in seven RCTs. The dif-
ference in the magnitude of patient-reported pain
between IOCM (iodixanol) versus LOCMs (ioxaglate,
iohexol, and iopamidol) was greater for peripheral and
carotid/intracerebral procedures compared to visceral
procedures. Although 3 of the 10 studies included in the
analysis reported no statistically significant difference in
the incidence of pain (Poirier et al, p = 0.062; Pugh et
al, p = 1.000; Siegel et al, p = 0.093) between iodixanol
vs. iopromide, iohexol, and ioxaglate, respectively
(Figure 3B), our meta-analysis favored IOCM (iodixanol)
compared to all LOCMs combined, with a summary RD
value of -0.188 (95% CI: -0.265, -0.112; p < 0.001) for
incidence of pain, regardless of the severity [18,19,21].
The overall effect size was -0.191, 95% CI: -0.305,
-0.077; p < 0.001 when patient-reported incidence of
pain was based on moderate or severe vs. none or mild
intensity. IOCM (iodixanol) was the favored CM both
when the trial data were analyzed individually against
each LOCM for which at least three studies were avail-
able (ioxaglate and iohexol) and for all LOCMs com-
bined as a group. The number of studies identified for
iopamidol (n = 1) and iomeprol (n = 1) was not ade-
quate to allow the meta-analysis for incidence of pain to
be performed for these LOCMs. However, the IOCM
iodixanol was favored when compared to iopamidol (p <
0.001) and to iomeprol (p = 0.007) [20,22].
Warmth Sensation
Of the 22 RCTs, 15 (68%; n = 5899) reported the inci-
dence of warmth with injection, and 13 studies (59%; n
= 7302) provided information on its severity. Injection-
related warmth was reported by more than 90% of
patients, irrespective of the CM used. With the excep-
tion of three trials, there were no statistically significant
differences between IOCM (iodixanol) and LOCMs (iox-
aglate, iohexol, iomeprol, iopromide, iopamidol) regard-
ing the incidence of warmth [15,18,23]. One of the two
studies that did not report severity data showed a signif-
icant difference between iodixanol (57%) and iohexol
(77%), p = 0.036 [18]. The meta-analysis of the warmth
data modestly favored IOCM (iodixanol) over LOCMs
(Figure 4, upper panel) with an effect size of -0.043
(95% CI: -0.074, -0.011; p = 0.008). This effect was more
pronounced when the incidence of warmth was evalu-
ated by severity (Figure 4, lower panel). The RD for the
latter was -0.201 (95% CI: -0.270, -0.131; p < 0.001).
Similarly, when the meta-analysis for incidence of
warmth (with or without the severity data) was per-
formed against each LOCM, iodixanol was favored over
ioxaglate, iopromide, and iohexol. The three studies
comparing iodixanol vs. iopamidol did not favor either
agent. No evidence of publication bias was noted among
the studies reporting CM-associated warmth.
Cold Sensation
Only five studies reported data (n = 450) on CM-
associated cold sensation experienced by patients under-
going radiological procedures [20,24-27]. Minimal rates
(< 5.3%) of mild coldness were reported by patients
given IOCM iodixanol. The meta-analysis of CM-asso-
ciated cold sensation (with or without severity) did not
show a difference between IOCM (iodixanol) and
LOCM with an overall effect size of 0.008 (95% CI:
-0.013, 0.030; p = 0.0449) using a fixed or random
effects model.
Multivariate Meta-regression Analysis
The results of the meta-regression analyses with RD of
each event as the dependent variable and increasing age
and proportion of women as the independent variables
are presented in Figure 5. With regard to incidence of
pain (moderate or severe vs. none or mild), there was a
slight increase of RDs with increasing age (Tau-squared
= 0.01467, slope = 0.00690 and intercept = -0.5137)
(Figure 5, Panel A), whereas the RD tended to decline
with and increasing percent of women enrolled in the
trials (Tau-squared = 0.0111, slope = -0.00663 and inter-
cept = 0.10932) (Figure 5, Panel B). The opposite age
and gender trends were found with warmth sensation as
the outcome (Figure 5, Panels C and D) with Tau-
squared values of 0.00768 and 0.0078, respectively.
Discussion
We found that the intra-arterial use of IOCM (iodixa-
nol) compared with individual LOCM agents or LOCM
as a group was associated with reduced frequency and
severity of pain, warmth, and discomfort reported by
patients in prospective, head-to-head, RCTs. Older age
was associated with greater effect sizes with respect to
pain but lesser effects with warmth. The opposite trends
were noted as the proportion of women increased in the
trials, suggesting both age and gender modify patient-
reported outcomes according to the osmolality of CM.
There was a moderate degree of heterogeneity among
the trials because of differences in trial design, reporting
methods of patient symptoms, and external consistency
between the trials. There was no evidence of publication
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the results of this analysis.
Our data are consistent with what is known about the
vascular biologic effects of iodinated CM. All forms of
iodinated CM position iodine on a single benzene ring
or a dimer of such rings. The presence or absence of
charged side chains, particle concentration in solution
(osmolality), viscosity, and iodine concentrations are the
main physiochemical characteristics that make each for-
mulation unique. Iodixanol is an iso-osmolar, nonionic,
dimer that is isotonic with blood. It is believed that this
formulation results in less deformation of cell mem-
branes in blood and the vascular endothelium. As a
result, there is an attenuated immediate release of hista-
mine from basophils and nitric oxide from vascular
endothelial cells. Thus, there is a blunted initial wave of
vasodilation throughout the body as CM travels through
the vasculature. In addition, with iso-osmolality, a less
pronounced vasoconstriction is anticipated following the
initial phase of endothelium-dependent vasodilation. As
a result, there is greater vascular stability in arterioles
that serve the skeletal muscles and skin in the extremi-
ties. This attenuates the activation of nociceptors in
nerves supplying both the neurovascular bundles as well
as the end-organs. Because the greatest physiochemical
difference between IOCM (iodixanol) and LOCM is
osmolality as opposed to iodine content or viscosity, we
believe, our data support osmolality being the main
determinant of symptoms after intravascular injection.
The clinical importance of ourf i n d i n g si sh i g h l i g h t e d
in the ever increasing use of iodinated contrast for intra-
vascular imaging procedures. Our results extend the
observations of Justesen and coworkers whose trial
included in our meta-analysis [15]. In this trial alone,
1225 patients were randomized to iodixanol and 1227 to
iopromide in conventional/digital subtraction angiogra-
phy of the femoral arterial system. The iodixanol group
reported statistically significantly less injection-asso-
ciated pain (0.9%) than the iopromide group (9.5%) (p <
0.001). In addition, 4.1% in the iodixanol group experi-
enced pain and/or severe heat sensation vs 19. 8% in the
iopromide group (p < 0.001). Our analysis suggests these
Figure 3 A. Incidence of CM-associated pain based on severity. B. Incidence of any pain (regardless of severity) associated with CM
injection. C. Meta-analysis of incidence of CM-associated pain (regardless of severity) - IOCM (iodixanol) vs. LOCMs.
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beds and left ventriculography.
Reduction in pain and discomfort is an important goal
for improving the overall tolerability of any procedure.
If symptoms related to CM cause tachycardia or body
motion, the procedure may be prolonged and the quality
of a variety of imaging tests could be affected. This
threatens the diagnostic accuracy and subsequent clini-
cal decision making. In addition, poor image quality
because of motion artifact may influence the outcomes
of an interventional procedure such as a vascular stent
placement planned from digital subtraction angiography.
Moreover, non-diagnostic studies often lead to repeated
examinations, exposing patients to additional injections
of contrast and higher doses of radiation. Thus, for all
of these reasons, the choice of IOCM over LOCM
would be supported in peripheral arteriography proce-
dures where higher degrees of discomfort or body
motion would be expected with injection.
Our analysis has all the limitations of any tabular meta-
analysis: the response variables measured, stratifications
reported, and the individual trial sample sizes. We did
not have information on the rates of injection, bolus size,
or the use of power injectors, or the use of conscious
sedation and analgesic medications which could have
influenced the overall size and concentration of CM
moving en bloc through the vasculature and its triggering
of nociceptors. Importantly, none of the studies had phy-
siologic correlates such as skin temperature, bioimpe-
dance, or plethysmography to investigate the
neurovascular origins of discomfort reported. We had
insufficient information on the injection site to draw con-
clusions on outcomes in typically very sensitive vascular
territories (distal upper limb and pudendal artery) as well
as on injection rates and CM concentration. We included
coronary angiography, which for the most part elicits few
symptoms, and thus, biased our findings to the null
hypothesis. This being considered, the large effect size,
internal and external consistency, and absence of publica-
tion bias all suggest the differential findings among the
CM are valid and likely to be reproduced in everyday
clinical practice. Finally, we did not have data on patient
motion and image quality, but we suspect in cases where
the discomfort was greater, there was more patient
motion and the possibility of reduction in image quality.
Figure 4 Meta-analysis of incidence of CM-associated warmth regardless of severity - IOCM (iodixanol) vs. all LOCMs (upper panel);
Meta-analysis of incidence of CM-associated warmth, moderate or severe vs none or mild severity - All LOCMs (lower panel).
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In conclusion, IOCM (iodixanol) is associated with less
frequent and severe patient discomfort characterized as
pain and warmth during intravascular administration
compared to the individual LOCM or LOCM as a
group. These data support difference in osmolality as
the major determinant of such symptoms with CM use.
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